Search

Your search keyword '"Carteni, Giacomo"' showing total 99 results

Search Constraints

Start Over You searched for: Author "Carteni, Giacomo" Remove constraint Author: "Carteni, Giacomo"
99 results on '"Carteni, Giacomo"'

Search Results

1. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

2. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

5. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

6. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

7. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

8. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

9. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

10. Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma

11. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

12. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

13. Erratum to: Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

17. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

19. SAFETY AND EFFICACY OF SUNITINIB IN METASTATIC RENAL CELL CARCINOMA (mRCC): PRELIMINARY ASSESSMENT OF AN ITALIAN EXPANDED-ACCESS PROGRAM (EAP) WITH SUBPOPULATION ANALYSIS: 1217

22. FLUOROURACIL (FU) PLUS FOLINIC ACID (FA) WITH IRINOTECAN (CPT-11) OR OXALIPLATIN (OHP) IN ADVANCED COLORECTAL CANCER (ACC) PATIENTS: PRELIMINARY SAFETY RESULTS OF A RANDOMIZED PHASE III MULTICENTER TRIAL OF THE GRUPPO ONCOLOGICO ITALIA MERIDIONALE (GOIM): 652

24. Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.

25. PAzopanib as first line in MEtastatic RCC patients: A “real-world” ITalian experience (PAMERIT study)—Preliminary results.

27. Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

28. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.

29. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

30. Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers

31. PD04-02 ADJUVANT SUNITINIB IN PATIENTS WITH HIGH RISK RENAL CELL CARCINOMA: SUBGROUP ANALYSES FROM S-TRAC TRIAL

32. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

33. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

34. Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.

35. The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

36. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?

37. MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)

38. Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC).

39. Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

41. Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).

42. Prognostic factors and validation of prognostic nomograms in patients (pts) treated with three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC): Results from an Italian survey.

44. Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.

45. Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastases survey.

46. Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy.

47. A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.

48. Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

49. Sunitinib in metastatic renal cell carcinoma patients with brain metastases

50. Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer

Catalog

Books, media, physical & digital resources